Gonadal and erectile dysfunction in diabetics.
Hijazi RA - Med Clin North Am - 01-JUL-2004; 88(4): 933-45, xi
From NIH/NLM MEDLINE
NLM Citation ID:
15308386 (PubMed)
Full Source Title:
Medical Clinics of North America
Publication Type:
Journal Article; Review; Review, Tutorial
Language:
English
Author Affiliation:
Department of Medicine, Veterans Affairs Medical Center, Houston, TX 77030, USA.
Authors:
Hijazi RA; Betancourt-Albrecht M; Cunningham GR
Number of References:
53
Abstract:
The high prevalence of erectile dysfunction in patients with diabetes is caused mainly by vascular and neurological conditions;nevertheless, hypogonadism may also contribute to erectile dysfunction and to changes in mood, libido, body composition, and bone density. Age, obesity, and the assay used to measure testosterone will affect the diagnosis of hypogonadism. This article focuses on the interaction of these conditions and attempts to explain possible mechanisms for observations reported in the literature.
Major Subjects:
- Diabetes Mellitus, Type 2 / * complications / diagnosis / drug therapy
- Hypogonadism / drug therapy / epidemiology / * etiology
- Impotence / epidemiology / * etiology / therapy
- Testosterone / * secretion / therapeutic use
Additional Subjects:
- Age Distribution
- Aged
- Comparative Study
- Cross-Sectional Studies
- Follow-Up Studies
- Humans
- Hypoglycemic Agents / therapeutic use
- Incidence
- Male
- Middle Aged
- Risk Assessment
- Treatment Outcome
- Vasodilator Agents / therapeutic use
Chemical Compound Name:
(Hypoglycemic Agents); (Vasodilator Agents); 58-22-0(Testosterone)